Andera Partners is strengthening its presence in the DACH region (Germany, Austria, German speaking Switzerland) by opening an office in Munich.

(To read the press release in German, please click here)

The management company has already been active in this region for several years, notably through its Andera Life Sciences activity. It has invested in companies such as Jenavalve, Noxxon, Probiodrug, and Allecra and, more recently, in T-Knife, Exciva and Tricares. Andera Partners will continue to focus on the biotech and medtech sectors in these markets, while preparing the ground for its SME, Mezzanine and Renewable Energy and Infrastructure funds.

“The German, Austrian and German speaking Swiss markets have traditionally been an interesting place for us to invest in exciting Life Sciences companies, and the region has become even more attractive recently. It therefore seemed appropriate and timely to strengthen our presence in these geographies with a local presence” said Olivier Litzka, Partner at Andera Life Sciences and coordinator of DACH activities. “Our interest in the DACH region is clearly threefold: 1/ Being closer to the ecosystem to identify the rising stars of life sciences companies, 2/ exploring opportunities for our growth capital, buy out, sponsorless mezzanine, renewable energy and infrastructure funds and 3/ attracting institutional investors as well as major family offices in Germany, Austria and Switzerland into our Andera family of funds.”

“We are highly committed to the DACH region, as demonstrated by the fact, that Olivier has now relocated from Paris to Munich to coordinate Andera Partners’ efforts to expand into the region. We have a true ambition to further grow pan-European and a partner building a presence is the ideal way to do it” said Raphael Wisniewski and Sylvain Charignon, the two Managing Partners of Andera Partners.

With more than 20 years of VC experience, 15 of which as a partner with Andera Life Sciences, Olivier Litzka, PhD, has extensive expertise with biotech and medtech startup companies, as well as with building relationships with Limited Partners.

Beyond its initial Life Sciences focus, the Munich office represents an additional showcase for Andera Partners’ overall activities in the DACH markets as well as a further step in Andera Partners’ international strategy. With existing offices in France and in Belgium, the DACH countries represent a third European region of priority for Andera Partners, on top of its investment activities in other European countries and in the US.

Share on :

More news